Chongqing beer will stop selling hepatitis B vaccine from now on

Will the topic of "hepatitis B vaccine", which has caused the sharp fluctuation of Chongqing beer stock price, once again arouse the attention of the capital market? Last night, Chongqing beer (600132) announced that it had received a written notice from the holding subsidiary Chongqing Jiachen Bioengineering Co., Ltd (Jiachen Biology), which will hold a "randomized, double-blind, multicenter phase II clinical study on the efficacy and safety of hepatitis B vaccine (synthetic peptide) combined with entecavir in the treatment of HBeAg positive chronic hepatitis B" (hereinafter referred to as "the randomized, double-blind, multicenter phase II clinical study")“ The blind data review meeting of the joint medication group) was held, and then the work of Unblinding was carried out In view of the significant risks of the research project, in order to ensure fair information disclosure, safeguard the interests of investors and avoid abnormal fluctuations in the company's stock price, Chongqing beer will be suspended from September 16, and will resume trading after the announcement of the main efficacy indicators of the combined drug group on September 27 On April 18 last year, Chongqing beer released a summary report on the clinical trials of the hepatitis B vaccine group alone The conclusion part shows that when the treatment dose is increased from 600ug / time to 900ug / time, there is no significant effect in the main efficacy index and secondary efficacy index Experts believe that the group alone is invalid, basically declaring the "death penalty" of hepatitis B vaccine It is understood that the single medication group is headed by the people's Hospital of Peking University, while the combined medication group is headed by the First Affiliated Hospital of Zhejiang University Medical College Hepatitis B vaccine combined with entecavir is also a phase II clinical study for the treatment of chronic hepatitis B patients Since February 2011, the number of trials has been 376, with a period of 96 weeks It has been recently completed, and is being unblinded and statistically analyzed Analyze and summarize the work Chongqing beer announced in August last year that it would complete the experiment and summary of the whole combined drug group, and it is expected to invest about 10 million yuan Last night, Deng Wei, Secretary of the board of directors of Chongqing beer, said that the announcement should prevail, and more inconveniences should be said It is understood that Chongqing beer has passed the proposal of withdrawing 102 million assets depreciation reserves for Jiachen biology, a subsidiary of the research and development of hepatitis B vaccine, saying that Jiachen company will no longer apply for phase III clinical trials of the hepatitis B vaccine alone group, nor will it open a new phase II clinical study of the alone group "There is also a life-saving straw in the theory of hepatitis B vaccine, but there is little hope." According to a new drug expert of a pharmaceutical listed company in our city, if hepatitis B vaccine combined with entecavir is more effective than entecavir alone in the treatment of chronic hepatitis B patients, then it is necessary to continue the research and development of hepatitis B vaccine, but the probability of significant efficacy is not great He pointed out that the current international treatment of AIDS is to take a combination of drugs, the effect is better than a single drug, known as "cocktail therapy." On Friday, Chongqing beer closed at yuan, up 0.83%.